Result for
Topic: Testing and Treatment
October 12, 2020
Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19
Among 86 pregnant and postpartum women with severe COVID-19 who received compassionate use of remdesivir, recovery rates were high (93% for pregnant women and 89% for postpartum women) and there were few serious adverse events (16% of all participants). At the beginning of treatment with remdesivir, 40% of pregnant women required invasive ventilation, compared to…
October 9, 2020
Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples
A study comparing the performance characteristics of four high-throughput assays for SARS-CoV-2 antibody detection indicated that for samples collected from patients 14 or more days after symptom onset, the Roche and Siemens assays had the highest sensitivities (96.6% and 98.3%, respectively) and specificities (100% for both) out of the four tests. The authors note that…
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY trial found that patients hospitalized with COVID-19 who received hydroxychloroquine did not have a lower incidence of death by 28 days after enrollment compared to those who received usual care. The randomized open-label platform trial found that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within…
Preemptive Interleukin-6 Blockade in Patients with COVID-19
Preemptive therapy with tocilizumab to prevent the consequences of cytokine storm was associated with early favorable outcomes in 77% of patients hospitalized with COVID-19 and death occurred in 6% of treated patients in a study of 64 patients in Spain. estimated mortality of 10 to 20% in comparably ill patients. [EDITORIAL NOTE: The lack of…
October 8, 2020
Extremely Potent Human Monoclonal Antibodies from Convalescent Covid-19 Patients
[Pre-print, not peer reviewed] Single cell sorting of 4277 SARS-CoV-2 spike protein specific memory B cells from 14 COVID-19 survivors identified 220 neutralizing antibodies that expressed as IgG. Among these, 3 monoclonal antibodies were potent enough to neutralize the wild type and DG14G mutant viruses in vitro at a concentration of <10 ng/mL, indicating they…
Remdesivir for the Treatment of Covid-19 – Final Report
Infusion of the antiviral drug remdesivir led to faster recovery time (median 10 vs. 15 days) and a non-significantly lower risk of death at 29 days (HR=0.73, 95% CI 0.52-1.03) in a randomized, placebo-controlled trial among patients hospitalized with COVID-19. Serious adverse events were reported in 131 of 532 (24.6%) patients in the remdesivir group…
October 7, 2020
Lilly Provides Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs
[Press release, not peer-reviewed] A combination of two monoclonal antibodies showed evidence of efficacy for treatment of mild-to-moderate COVID-19. A randomized, double-blind, placebo-controlled Phase 2 trial (BLAZE-1 trial) showed that combination therapy with two of Lilly’s SARS-CoV-2 neutralizing antibodies (LY-CoV555 and LY-CoV016) administered to patients with mild-to-moderate COVID-19 (112 received antibody, 156 received placebo) reduced viral…
October 6, 2020
Temporal Analysis of COVID-19 Convalescent Plasma Donations Reveals Significant Decrease in Neutralizing Capacity Over Time
[Pre-print, not peer reviewed] Analysis of 981 COVID-19 convalescent plasma (CP) samples from 196 donors shows that over time, neutralizing capacities of CP can decrease below recommended FDA levels of 50% neutralization (PRNT50%) and 90% neutralization (PPRNT90%). The most significant decreases of PRNT50% titer occurred at more than 43 days post initial donation, suggesting a…
Lopinavir–Ritonavir in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial
A randomized open-label trial (RECOVERY trial) found that among patients admitted to hospital with COVID-19, treatment with lopinavir-ritonavir was not associated with reduction in 28-day all-cause mortality (RR=1.03, 95%CI: 0.91-1.17), duration of hospital stay (RR=0.98, 95%CI: 0.91-1.05), or progression to mechanical ventilation or death (RR=1.09, 95%CI: 0.99-1.20). 23% of patients receiving lopinavir-ritonavir died within 28…
October 5, 2020
Association of Corticosteroids Use and Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis
A systematic review with 1 randomized trial and 19 cohort studies (16,977 hospitalized COVID-19 patients) reported that corticosteroid therapy was not associated with a reduction in short-term mortality (RR=0.9, 95%CI 0.7-1.2) but possibly with a delay in viral clearance (RR=1.5, 95%CI 1.1-1.9). The authors call for caution in interpretation due to discordant results observed between…
Previous page Next page